ALBO - Albireo Pharma, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
30.17
+0.44 (+1.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close29.73
Open29.99
Bid14.22 x 1100
Ask40.00 x 800
Day's Range29.48 - 30.80
52 Week Range20.25 - 39.87
Volume25,369
Avg. Volume85,443
Market Cap361.132M
Beta2.31
PE Ratio (TTM)N/A
EPS (TTM)-2.16
Earnings DateDec 15, 2016 - Dec 19, 2016
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est63.50
Trade prices are not sourced from all markets
  • GlobeNewswire10 days ago

    Albireo to Present at Wedbush PacGrow Healthcare Conference

    BOSTON, Aug. 08, 2018-- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive ...

  • GlobeNewswire11 days ago

    Albireo Reports Second Quarter 2018 Financial Results

    A4250 Phase 3 trial in PFIC underway. A4250 granted rare pediatric disease designation, eligible to apply for priority review voucher. Management to host conference call and webcast today at 8:30 a.m. ...

  • ACCESSWIRE11 days ago

    Albireo Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Albireo Pharma, Inc. (NASDAQ: ALBO ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 8:30:00 AM Eastern ...

  • GlobeNewswire15 days ago

    Albireo to Report Second Quarter 2018 Financial Results, and Host Conference Call and Webcast on August 7, 2018

    BOSTON, Aug. 02, 2018-- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that its second quarter financial results will ...

  • GlobeNewswire18 days ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Finisar, Albireo Pharma, Corporate Office Properties Trust, Ocean Power Technologies, Depomed, and Potbelly — New Research Emphasizes Economic Growth

    NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Finisar ...

  • GlobeNewswire24 days ago

    Albireo Appoints Patrick Horn MD, PhD as Chief Medical Officer

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Dr. Patrick Horn as Chief Medical Officer.  Dr. Horn will succeed Dr. Paresh Soni who will step down from the Chief Medical Officer role but will continue as a consultant to the Company. “Pat brings to Albireo a unique combination of pediatric, orphan and Phase 3-to-approval experience that will be invaluable as we reach a new stage of growth at the Company,” said Ron Cooper, President and Chief Executive Officer of Albireo.

  • GlobeNewswire2 months ago

    Albireo Added to Russell 2000® Index

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that it has been added to the Russell 2000® Index as part of the annual reconstitution of the Russell stock indexes, effective upon U.S. market close on June 22, 2018. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity market and is a subset of the Russell 3000, representing approximately 10 percent of the total market capitalization of that index. Russell indexes are widely used by investment managers and institutional investors for index funds, and as benchmarks for active investment strategies. “We are pleased to have been selected for inclusion in the Russell 2000 Index,” said Ron Cooper, President and Chief Executive Officer of Albireo.

  • GlobeNewswire2 months ago

    Albireo Appoints Jason G. Duncan as General Counsel and Secretary

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the appointment of Jason G. Duncan as General Counsel and Secretary. In this role, Mr. Duncan will be responsible for Albireo’s global legal affairs, and serve as a strategic advisor to the executive team and board of directors. “With the initiation of our Phase 3 trial of A4250 in progressive familial intrahepatic cholestasis (PFIC), Albireo has entered the next stage of growth, and we must continue to build the company for the future,” said Ron Cooper, President and Chief Executive Officer of Albireo.

  • GlobeNewswire2 months ago

    FDA Grants Rare Pediatric Disease Designation to A4250; Albireo Eligible to Apply for Priority Review Voucher

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the U.S. Food and Drug Administration (FDA) has granted rare pediatric disease designation to lead product candidate A4250, an ileal bile acid transporter (IBAT) inhibitor, for the treatment of progressive familial intrahepatic cholestasis (PFIC), a rare and life-threatening liver disease with no approved pharmacologic treatment option. “This designation affirms Albireo’s eligibility to apply for a rare pediatric disease priority review voucher upon submission of a new drug application for A4250 and highlights the serious, life-threatening manifestations of PFIC,” said Ron Cooper, President and Chief Executive Officer of Albireo.

  • GlobeNewswire2 months ago

    Albireo Elects Anne Klibanski and Stephanie Okey to Board of Directors

    Albireo Pharma, Inc. (ALBO), a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced the election of Anne Klibanski, M.D., and Stephanie Okey, M.S., to its board of directors. “Albireo has reached a new stage in its growth, and I am delighted to welcome two very high-caliber leaders to our board,” said David Chiswell, Ph.D., Chairman of Albireo's Board of Directors. “Anne is a proven leader with substantial rare disease research, clinical and hospital system experience, which will be helpful in guiding our development efforts.

  • GlobeNewswire3 months ago

    Albireo to Present at Jefferies 2018 Global Healthcare Conference

    BOSTON, May 29, 2018-- Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief Executive ...

  • ACCESSWIRE3 months ago

    Blog Exposure - Trevena Showcases Data from ATHENA Phase-3 Study at the American Society of Colon and Rectal Surgeons 2018 Annual Scientific Meeting

    LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Trevena,Inc. (NASDAQ: TRVN), all you need to do is sign up now by clicking thefollowing link www.active-investors.com/registration-sg/?symbol=TRVN as the Company’s latest news hit the wire. OnMay 22, 2018, the Company, which is a biopharmaceutical organization developinginnovative therapies based on breakthrough science to benefit patients and healthcareproviders confronting serious medical conditions, announced that it showcasedtwo presentations at the American Society of Colon and Rectal Surgeons 2018Annual Scientific Meeting. Active-Investors.com is currently working on the researchreport for Albireo Pharma, Inc. (NASDAQ: ALBO), which also belongs to the Healthcaresector as the Company Trevena.

  • ACCESSWIRE3 months ago

    Albireo Pharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 17, 2018 / Albireo Pharma, Inc. (NASDAQ: ALBO ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 17, 2018 at 8:30 AM Eastern Time. To ...

  • ACCESSWIRE5 months ago

    Wired News – Agios Pharmaceuticals Doses First Patient in AG-270 Phase-1 Dose-Escalation Trial in MTAP-Deleted Tumors

    Stock Monitor: Albireo Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Agios Pharma, Inc. (NASDAQ: AGIO ). If ...

  • ACCESSWIRE5 months ago

    Wired News – Zosano Reports Enrollment Milestone in its M207-ADAM Study

    Stock Monitor: Albireo Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 20, 2018 / Active-Investors.com has just released a free research report on Zosano Pharma Corp. (NASDAQ: ZSAN ) ("Zosano"). ...